Researchers have identified a new role for the enzyme EZH2 in promoting the progression of aggressive, treatment-resistant prostate cancers. Their study suggests that targeting EZH2’s alternative functions could restore the effectiveness of androgen receptor inhibitors and enhance the potential of immunotherapies in these cancers, offering new hope for patients facing this tough diagnosis. New Insights […]
Source link